BRCA1 and serous adenocarcinoma: Previous research has indicated that despite most patients receiving adjuvant chemotherapy based on the regimen used for serous carcinomas, OCCC is prone to develop resistance to first-line classic platinum-based chemotherapy drugs [41], which may also be related to the low prevalence of BRCA1/2 mutations in OCCC [42].